[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
The University of Texas MD Anderson Cancer Center · Sunnybrook Health Science Centre · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
302
total citations
- FWCI
- 105.91
- Percentile
- 100%
- References
- 28
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Octreotide
- Medicine
- Neuroendocrine tumour
- Neuroendocrine tumors
- DOTA
- Urology
- Internal medicine
- Nuclear medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.